title: Efficacy of irreversible electroporation in human pancreatic adenocarcinoma: advanced murine model.
abstract: Irreversible electroporation (IRE) is a promising cell membrane ablative modality for pancreatic cancer. There have been recent concerns regarding local recurrence and the potential use of IRE as a debulking (partial ablation) modality. We hypothesize that incomplete ablation leads to early recurrence and a more aggressive biology. We created the first ever heterotopic murine model by inoculating BALB/c nude mice in the hindlimb with a subcutaneous injection of Panc-1 cells, an immortalized human pancreatic adenocarcinoma cell line. Tumors were allowed to grow from 0.75 to 1.5 cm and then treated with the goal of complete ablation or partial ablation using standard IRE settings. Animals were recovered and survived for 2 days (n = 6), 7 (n = 6), 14 (n = 6), 21 (n = 6), 30 (n = 8), and 60 (n = 8) days. All 40 animals/tumors underwent successful IRE under general anesthesia with muscle paralysis. The mean tumor volume of the animals undergoing ablation was 1,447.6 mm(3) ± 884). Histologically, in the 14-, 21-, 30-, and 60-day survival groups the entire tumor was nonviable, with a persistent tumor nodule completely replaced fibrosis. In the group treated with partial ablation, incomplete electroporation/recurrences (N = 10 animals) were seen, of which 66% had confluent tumors and this was a significant predictor of recurrence (P < 0.001). Recurrent tumors were also significantly larger (mean 4,578 mm(3) ± SD 877 versus completed electroporated tumors 925.8 ± 277, P < 0.001). Recurrent tumors had a steeper growth curve (slope = 0.73) compared with primary tumors (0.60, P = 0.02). Recurrent tumors also had a significantly higher percentage of EpCAM expression, suggestive of stem cell activation. Tumors that recur after incomplete electroporation demonstrate a biologically aggressive tumor that could be more resistant to standard of care chemotherapy. Clinical correlation of this data is limited, but should be considered when IRE of pancreatic cancer is being considered.
authors.affiliation: Division of Surgical Oncology, Department of Surgery, University of Louisville , Louisville, Kentucky, USA.
authors.forename: Prejesh
authors.initials: P
authors.lastname: Philips
authors.affiliation: Division of Surgical Oncology, Department of Surgery, University of Louisville , Louisville, Kentucky, USA.
authors.forename: Yan
authors.initials: Y
authors.lastname: Li
authors.affiliation: Division of Surgical Oncology, Department of Surgery, University of Louisville , Louisville, Kentucky, USA.
authors.forename: Suping
authors.initials: S
authors.lastname: Li
authors.affiliation: Division of Surgical Oncology, Department of Surgery, University of Louisville , Louisville, Kentucky, USA.
authors.forename: Charles R
authors.initials: CR
authors.lastname: St Hill
authors.affiliation: Division of Surgical Oncology, Department of Surgery, University of Louisville , Louisville, Kentucky, USA.
authors.forename: Robert Cg
authors.initials: RC
authors.lastname: Martin